The Expression Of Mn1 In Acute Myeloid Leukemia And Its Prognostic Significance In Other Known Genetic Markers

Objective1. To explore the MN1 expression levels in patients with acute myeloid leukemia (AML) and compare MN1 expression levels with clinical datas.2. To evaluate the prognostic value of MN1 in context of other known cytogenetic and molecular markers.Methods1. MN1 expression levels were detected by quantatitive reverse transcription PCR (qRT-PCR), including peripheral blood or bone marrow samples of 75 AML patients, 17 patients in complete remission (CR) and 11 normal controls. Analysis the relationship of MN1 expression levels with age,sex,WBC,hemoglobin,platelet,CR rate and early death. Logistic regression was used for multivariate analysis.2. The mutation status of both NPM1 and FLT3 were studied. Allele-specific PCR was used to detect both NPM1 A and B mutantions. The expression levels of MN1 were compared in context of different cytogenetic and molecular markers.χ2 test was used for comparing the rate and Kroskal-Wallis H Rank sum test for multiple groups.Results1. There was no difference of MN1 expression levels in newly diagnosed,relapsed and CR groups. However, when dynamic observation in eight cases, the MN1 expression levels of 4 patients in CR remained high compared with those before induction, 3 cases relapsed within 5-6 months, and the MN1 expression levels of these 3 patients were higher than median levels when diagnosed. High MN1 expression was associated with early death (P=.016), Logistics Regression showed that age (P=.011) and MN1 expression (P=.004) was the risk factor of early death.2. Allele-specific PCR to detect both NPM1 A and B mutants was rapid, simple and sensitive. No difference of expression level of MN1 was found in different AML risk stratification. In 75 cases of newly diagnosed /relapsed AML, low MN1 expression level were related with NPM1+/FLT3- status (P=0.009) when compared with high expression group. This difference remained statistically significant when calculated only for 64 newly diagnosed AML (P=.01).Conclusion1. The continued high expression level of MN1 might be a predictor of high relapse rate; high MN1 expression was associated with early death, age was a confounding factors of early death, but after excluding the influence of age, MN1 expression was also the risk factor of early death.2. Low MN1 expression were related with NPM1+/FLT3- status whether in the newly diagnosed/relapsed AML or newly diagnosed AML .